MENU

Why these 4 ASX shares are ending the week deep in the red

It has been a disappointing end to the week for the benchmark S&P/ASX 200 (Index: ^AXJO) (ASX: XJO). In afternoon trade the index is down 1.3% to 5,711 points.

Four shares which have fallen significantly more than average today are listed below. Here’s why they are ending the week deep in the red:

The Ellex Medical Lasers Limited (ASX: ELX) share price is down 5% to $1.02 following the release of a trading update. According to the release, the medical device company expects to post a loss before tax of $2 million in FY 2017. This has been blamed on a stronger Australian dollar and investment in its iTrack device.

The Mayne Pharma Group Ltd (ASX: MYX) share price has fallen almost 4% to 95.2 cents. Whilst I think the pharmaceutical company’s shares are arguably dirt cheap right now, until the Trump Administration has finalised its plans on generic drug prices, I would suggest investors stay clear of the company’s shares.

The OceanaGold Corporation (ASX: OGC) share price is down 6.5% to $3.34 following the release of its second-quarter update. The market appears to have been left underwhelmed by management’s full-year production guidance of between 550,000 and 600,000 ounces of gold. Whilst its shares are cheaper now, I still feel there is better value for money elsewhere in the sector.

The Webjet Limited (ASX: WEB) share price has fallen 7% to $11.80 after the online travel agent advised that its auditor BDO Audit disagreed with a technical accounting matter relating to its financial statements for the year ending 30 June 2017. If BDO’s methodology were applied to its full-year results, it would reduce EBITDA by $11.5 million. Today’s decline could potentially be a buying opportunity in my opinion.

As well as Webjet, I think these growth shares could have fallen into the buy zone today.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks mean stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.